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Trace element status and hypothyroidism: A systematic review and meta-
analysis 
Abstract 
Background: The metabolism of thyroid hormones has been linked with alterations in trace 
element levels. However, previous reports comparing trace element levels in hypothyroid 
patients and healthy individuals had yielded equivocal results. Therefore, the aim of this meta-
analysis was to investigate the association between trace element (selenium (Se), zinc (Zn), iron 
(Fe), manganese (Mn), copper (Cu), magnesium (Mg) and lead (Pb)) concentrations in 
hypothyroid patients and healthy subjects.  
Methods: Electronic databases including PubMed, Scopus, Embase, and Web of Science were 
searched systematically until October 2018. Twenty-five observational studies were included. 
Hedges’ g was used to represent effect sizes, due to trace element levels being presented in 
different units among studies.  
Results: Our results revealed that lower Se concentration in patients with hypothyroidism 
compared with controls (Hedges’ g= −0.45; 95% CI = [−0.88, -0.02]; P = 0.042). In the subgroup 
analysis, Zn level was found to be lower in overt hypothyroid patients (Hedges’ g= −1.19; 95% 
CI = [−2.33, -0.04]; P = 0.04), while Fe (Hedges’ g= −1.11; 95% CI = [-2.21, -0.02]; P = 0.046) 
and Se (Hedges’ g= −0.51; 95% CI = [-0.86, -0.16]; P = 0.004) levels were significantly lower in 
subclinical hypothyroidism.  
Conclusion: We found lower Se concentration in patients with hypothyroidism. In addition, we 
found decreased concentration of Zn in overt hypothyroid patients and decreased Fe and Se level 
in subclinical hypothyroidism. Further studies, with higher quality and larger sample sizes, are 
required to explicate the link between trace element status and hypothyroidism. 
Key Words: Trace elements, Hypothyroidism, Meta-analysis 
 
Introduction 
Hypothyroidism is a major endocrine disorder which is defined as a disturbance in levels of 
circulating thyroid hormones; whilst autoimmune disorders, irradiation, or thyroid resection are 
considered to be potential etiological triggers [1]. The prevalence of hypothyroidism is reported 
to be up to two percent in geographical areas with sufficient iodine intake [2]. Thyroid hormones 
exert several physiological functions in the human body; such as regulation of body temperature, 
modulation of carbohydrates, lipids and proteins metabolism and also regulation of electrolytes 
and minerals metabolism [3]. 
Several trace elements like selenium (Se) and zinc (Zn) are  involved in the synthesis and 
metabolism of thyroid hormones [4]. Furthermore, Se is a cofactor of iodothyronine deiodinase , 
which converts T4 to T3, and plays an imperative role in the regulation of thyroid hormones 
synthesis. Se conceivably acts as a glutathione reductase and glutathione peroxidase cofactor, 
which protects the thyroid gland against oxidative stress [5]. Zn is reported to be essential for 
optimal thyroid function [6], is essential in thyroid hormones conversion [7], and is also known 
as the cofactor of thyrotropin releasing hormone biosynthetic enzyme [7, 8]. Iron (Fe) enhances 
the activity of the thyroid peroxidase enzyme, which causes iodine binding to thyroid hormones 
[9, 10]. 
Previous reports evaluating the association between the circulating levels of trace element and 
hypothyroidism have shown conflicting results; with some studies [4, 11, 12] indicating 
increased circulating levels of trace elements, whilst others [12-15] have reported decreased 
concentrations. Therefore, the aim of the present meta-analysis was to summarize current 
evidence on the circulating levels of Zn, manganese (Mn), copper (Cu), Se, magnesium (Mg), Fe 
and lead (Pb) levels between hypothyroid patients and healthy human adults. 
Methods 
Search Strategy 
We searched the databases PubMed, Science Direct, Embase and Scopus up to October 29, 2018. 
Search strategies including the key terms and the queries for each database are presented in the 
supplementary table 1.  
Selection Criteria 
Studies were included in the final analysis if they: 1) used case-control or cross-sectional design; 
2) conducted investigations on adults cases with hypothyroidism (age > 18 years) and healthy 
controls; 3) reported at least the mean and standard deviation of one of the trace elements (Zn, 
Mg, Se, Fe, Cu, Mn, Pb) in serum or plasma levels. Studies were excluded if they: 1) were trials, 
animal studies, case reports, conference papers, letters, editorial or reviews studies; 2) did not 
have adequate information to be extracted; 3) conducted on children or pregnant women; 4) were 
uncontrolled studies or conducted on non-healthy controls; 5) reported the levels of trace 
elements in erythrocytes. All studies were separately assessed by two investigators to determine 
adherence to selection criteria.  
Data extraction 
Data extraction was independently performed by two authors (HM and ST) using the standard 
form of pre-designed data collection. The following data was extracted from articles: first 
author’s name, year of publication, country, study design, sample size, mean age, proportion of 
male in groups, matched variables between the case and control group, body mass index and 
levothyroxine use. 
Quality assessment 
Two reviewers (HM and ST) scored the included studies using a Newcastle–Ottawa Scale (NOS) 
[16], including 3 major domains : selection of participants (0-4 stars), comparability of groups 
(0-2stars) and ascertainment of outcome (0-3stars). Scores of ≤ 3, 4–6 and ≥ 7 were considered 
as low, moderate and high quality studies respectively. Any disagreement in quality assessment 
was resolved through panel discussion. 
Statistical Analysis 
We calculated the standardized mean difference (SMD) with 95% CI using the Hedges statistic. 
Random effect model based on Inverse-Variance method was used in STATA (version 13) to 
pool the data. We assessed and quantified heterogeneity using heterogeneity chi-squared test 
with P-value less than 0.1 and I2 statistic over 50% considered as significant heterogeneity 
among studies. We ran a subgroup analysis for the case category variable (whether cases belong 
to category 1 or 2). Sensitivity analysis was performed to check whether the results were 
sensitive to the exclusion of one or more studies. We used Begg’s and Egger’s tests to check for 
the publication bias, and finally, trim and fill analysis was performed to check if observed 





Figure 1 illustrates the PRISMA flow diagram of studies through the selection process for 
inclusion in the systematic review and meta-analysis. A total of 818 studies identified from 
Medline, Embase, Scopus and Web of science databases. Five hundred and forty-one records 
were screened by title and abstract, and after duplicates were removed, 474 records were 
excluded. Among 67 remaining studies, 42 articles were excluded by full-text assessment. The 
most common reasons for exclusion were inappropriate data reporting (n=10), unavailable full 
texts (n=3), conducted on pregnant women (n=3), children (n=5), goiter (n=2) or hyperthyroid 
subjects (n=11), and inappropriate control group (n=8). Finally 25 case-control or cross-sectional 
studies included in the present meta-analysis [3, 4, 11-15, 17-34]. From these studies 11, 10, 9, 8, 
6, 4 and 3 articles reported Mg [3, 13, 15, 17, 18, 20, 22, 28-30, 34], Zn [4, 11-15, 20, 23, 27, 
29], Se [4, 12, 13, 19-21, 24, 32, 33], Cu [4, 11-14, 20, 23, 29], Fe [4, 11, 20, 25, 26, 28], Mn [4, 
11-13] and Pb [4, 11, 29], respectively. 
Study characteristics 
The characteristics of the included studies are reported in Table 1. Included studies were 
published in numerous countries between 1996 and 2018. The selected studies contained overt 
hypothyroidism [3, 4, 11-15, 17-19, 22-31, 33, 34], subclinical hypothyroidism [17, 20, 21, 24, 
26, 27, 29, 31, 32] and euthyroid [17, 19] diagnosed participants, while all the studies contained 
a control group of healthy subjects. Most records presented both genders in adults and elderly. 
Twenty-three articles [3, 4, 11-15, 17-28, 30-32, 34] entered into meta-analyses presented data 
on serum levels of trace elements, whereas two articles [29, 33], reported data on plasma levels.  
Quality assessment 
The results of NOS, to indicate the quality assessment of included articles, is showed in Table 2. 
Among included studies, 12 records [11, 17, 19, 20, 23, 24, 27, 28, 30-32, 34] were identified as 
high quality (NOS ≥ 7) and the remaining studies [3, 4, 12-15, 18, 21, 22, 25, 26, 29, 33] were 
identified as moderate quality (NOS=4-6).  
Meta-analysis 
Data from 12 studies [4, 11-15, 20, 23, 27, 29] were analysed in a random-effects model to 
compare the serum/plasma Zn levels in hypothyroid patients and healthy controls. As indicated 
in Figure 2, pooled effect size revealed that serum Zn levels in subjects with hypothyroidism 
were not statistically different with those of healthy controls (Hedges’ g= -0.84; 95% CI = [-
1.74, 0.06]; P = 0.06). However, significant heterogeneity was detected across the studies 
(I2=97.5 %, P<0.001). Despite the classification of studies based on disease severity, we could 
not detect potential source of observed heterogeneity. However, significant differences in pooled 
effect size of Zn levels were observed in studies conducted on overt hypothyroidism (Hedges’ g= 
−1.19; 95% CI = [−2.33, -0.04]; P = 0.04), while there were non-significant differences in 
subjects with subclinical hypothyroidism (Hedges’ g= 0.15; 95% CI = [-1.23, 1.53]; P = 0.83). 
The results of subgroup analysis are shown in Figure 2. In addition, sensitivity analysis showed 
that the exclusion of Shah-a study [27] (Hedges’ g: -1.02; 95% CI: -1.99, -0.11), Shah-b study 
[27] (Hedges’ g: -1.04; 95% CI: -1.31, -0.06), and Rasic-Milutinovic study [4] (Hedges’ g: -1.12; 
95% CI: -2.02, -0.21) from the analysis changed the overall effect. There was no evidence of 
publication bias among included studies (P=0.21, Begg's test). Nevertheless, results of Egger's 
test showed a significant publication bias (P=0.03). However, trim-and-fill analyses yielded 
results similar to the original. 
The pooled effect size of 12 studies [4, 12, 13, 19-21, 24, 32, 33] revealed that serum/plasma Se 
levels in subjects with hypothyroidism was statistically different with those of healthy controls 
(Hedges’ g= −0.45; 95% CI = [−0.88, -0.02]; P = 0.042) (Figure 3). However, significant 
heterogeneity was detected across the studies (I2=92.2, P<0.001). Subgroup analysis, based on 
disease severity, could not detect any potential source of observed heterogeneity. However, 
significant differences in pooled effect size of Se levels were observed in studies conducted on 
subclinical hypothyroidism (Hedges’ g= −0.51; 95% CI = [-0.86, -0.16]; P = 0.004), while there 
were non-significant differences in subjects with overt hypothyroidism (Hedges’ g= -0.53; 95% 
CI = [-1.44, 0.37]; P = 0.249) (Figure 3). In addition, sensitivity analysis showed that the 
exclusion of Wimmer 2014 study [32] (Hedges’ g: -0.46; 95% CI: -0.93, 0.01), Federige a 2017 
study [21] (Hedges’ g: -0.44; 95% CI: -0.90, 0.02), Pedersen a 2013 study [19] (Hedges’ g: -
0.50; 95% CI: -1.02, 0.02), Faisal Rashid 2010 study [13] (Hedges’ g: -0.17; 95% CI: -0.43, 
0.10), Eham 2008 study [12] (Hedges’ g: -0.46; 95% CI: -0.94, 0.02), Nourbakhsh b 2015 study 
[24] (Hedges’ g: -0.45; 95% CI: -0.91, 0.01), Erdal 2008 study [20] (Hedges’ g: -0.37; 95% CI: -
0.83, 0.06), and Pedersen b 2013 study [19] (Hedges’ g: -0.50; 95% CI: -1.02, 0.01) from the 
analysis changed the overall effect. There was no evidence of publication bias among included 
studies (P=0.583, Begg's test & P=0.211, Egger’s test).  
Fourteen studies [3, 13, 15, 17, 18, 20, 22, 28-30, 34] reported data regarding the serum/plasma 
Mg levels in hypothyroid patients and healthy controls. As indicated in Figure 4, pooled effect 
size revealed that serum Mg levels in subjects with hypothyroidism was not statistically different 
with those of healthy controls (Hedges’ g= −0.02; 95% CI = [−0.98, 0.94]; P = 0.970). However, 
significant heterogeneity was detected across the studies (I2=98%, P<0.001). Subgroup analysis 
neither changed the results nor detected any potential source of heterogeneity. Moreover, 
sensitivity analysis showed that the results were not sensitive to any of the studies. Besides, there 
was no evidence of publication bias among included studies (P=0.622, Begg's test & P=0.582, 
Egger’s test).  
Data from 9 studies [4, 11-14, 20, 23, 29] were analysed in a random-effects model to compare 
the serum/plasma Cu levels in hypothyroid patients and healthy controls. As indicated in Figure 
5, pooled effect size revealed that serum Cu levels in subjects with hypothyroidism was not 
statistically different with those of healthy controls (Hedges’ g= −0.09; 95% CI = [−0.40, 0.23]; 
P = 0.586). However, significant heterogeneity was detected across the studies (I2=78%, 
P<0.001). Subgroup analysis yielded no change in the results, nevertheless heterogeneity was 
attenuated in studies conducted in overt hypothyroidism (I2=83.3%, P<0.001; Figure 5). Findings 
from the sensitivity analysis revealed that the exclusion of any single study from the analysis did 
not alter the overall effect. Besides, there was no evidence of publication bias among included 
studies (P=0.677, Begg's test & P=0.896, Egger’s test).  
The pooled effect size from 8 studies [4, 11, 20, 25, 26, 28] showed that serum/plasma Fe levels 
in subjects with hypothyroidism were not statistically different with those of healthy controls 
(Hedges’ g= −0.77; 95% CI = [−1.55, 0.01]; P = 0.053) (Figure 6). However, significant 
heterogeneity was detected across the studies (I2=97.6 %, P<0.001). Despite the classification of 
studies based on disease severity, we could not detect potential source of observed heterogeneity. 
However, significant differences in pooled effect size of Fe levels were observed in studies 
conducted on subclinical hypothyroidism (Hedges’ g= −1.11; 95% CI = [-2.21, -0.02]; P = 
0.046), while there were non-significant differences in subjects with overt hypothyroidism 
(Hedges’ g= -0.56; 95% CI = [-1.76, 0.64]; P = 0.362) (Figure 6). In addition, sensitivity 
analysis showed that the exclusion of Hanif 2017 [11] (Hedges’ g: -1.05; 95% CI: -1.68, -0.43) 
from the analysis changed the overall effect. There was no evidence of publication bias among 
included studies (P=0.216, Begg's test & P=0.258, Egger’s test).  
Four studies [4, 11-13] reported data regarding the serum/plasma Mn levels in hypothyroid 
patients and healthy controls. As indicated in Figure 7, pooled effect size revealed that serum 
Mn levels in subjects with hypothyroidism was not statistically different with those of healthy 
controls (Hedges’ g= 0.04; 95% CI = [−1.37, 1.44]; P = 0.960). However, significant 
heterogeneity was detected across the studies (I2=97.4%, P<0.001). In addition, sensitivity 
analysis showed that the exclusion of Faisal Rashid (2010) study [13] (Hedges’ g: 0.87; 95% CI: 
0.03, 1.71) from the analysis changed the overall effect. There was no evidence of publication 
bias among included studies (P>0.999, Begg's test & P=0.675, Egger’s test).  
The pooled effect size from 4 studies [4, 11, 29] reported data regarding the serum/plasma Pb 
levels in hypothyroid patients and healthy controls. The pooled effect size revealed that serum Pb 
levels in subjects with hypothyroidism was not statistically different with those of healthy 
controls (Hedges’ g= 0.04; 95% CI = [−0.83, 0.92]; P = 0.920) (Figure 8). However, significant 
heterogeneity was detected across the studies (I2=90.8%, P<0.001). Finding from sensitivity 
analysis indicated that the exclusion of Joao a (2007) study [29] (Hedges’ g: 0.51; 95% CI: 0.04, 
0.98) from the analysis changed the overall effect. Moreover, there was no evidence of 
publication bias among included studies (P=0.174, Begg's test & P=0.201, Egger’s test).  
 
Discussion 
To the author’s knowledge, this is the first systematic review and meta-analysis to have 
investigated the circulating level of trace elements in patients suffering from hypothyroidism. 
The results obtained from twenty-five observational studies showed lower Se concentration in 
patients with hypothyroidism compared to the normal subjects. There was no significant 
difference in the concentration of Zn, Fe, Cu, Mn, Mg and Pb levels between normal group and 
patients with hypothyroidism. Subgroup analysis based on disease severity was performed to 
find-out potential sources of heterogeneity. Subgroup analysis revealed that Zn levels was 
significantly lower in overt hypothyroidism, while serum/plasma Se and Fe levels were 
significantly lower in subclinical hypothyroidism compared to healthy participants. In addition, 
overall estimate of effect size was influence by elimination of several studies; sensitivity analysis 
showed that results changed to a significant value for Zn, Se, Fe, Mn, Pb. Therefore, findings 
must be interpreted with caution.  
Pooled effect size showed lower Se concentration in patients with hypothyroidism. These 
findings are in keeping with most recent studies that indicate abnormal metabolism of Se in 
hypothyroidism [12, 13, 19, 20, 32, 35]. These studies reported that there is an association 
between Se status and thyroid hormone metabolism, in addition, Se levels were reduced in 
autoimmune thyroid disorders [12, 32]. The results of previous meta-analyses [5, 36, 37] 
indicated that Se supplementation might improve Hashimoto’s thyroiditis; in essence Se 
decreased antibody levels and dosage of levothyroxine. Moreover, evidence from animal studies 
[38, 39] revealed that a Se deficient diet characterized by reduced T3 and elevated T4 
concentrations. The exact mechanism explaining lower Se concentration in hypothyroidism is 
not completely understood, however it may conceivably be attributed to the immunomodulatory 
and anti-proliferative properties of Se [40]. Most thyroid disorders are self-immune diseases, 
which are characterized by activated immune system and inflammation [24], thus, the systemic 
inflammatory setting may have decreased Se levels. n the other hand reduced Se concentration 
may lead to impairment in the immune function of patients with Hashimoto’s thyroiditis  [24]. 
Other possible explanations may be attributed to selenium interference in reducing free radicals 
production and protecting against oxidative stress-associated disorders [41]. The biological role 
of selenium in redox control and antioxidative defense is exerted by selenoproteins like the 
glutathione peroxidases, thioredoxin reductases, and other selenoproteins, and as a result, Se 
deficiency leads to increased oxidative damage to the thyroid gland [42]. 
Findings in the current study demonstrated a significantly lower level of serum Zn in overt 
hypothyroid patients compared with controls. Previous clinical trials [43-45] showed a positive 
beneficial effect of Zn supplementation on FT3 levels. Zn deficiency reportedly decreases thyroid 
hormones, but Zn supplementation adversely affected thyroid function and metabolic activity of 
these hormones. The possible mechanisms which clarify the possible correlation between Zn 
deficiency and hypothyroidism might be due to impairment of gastrointestinal absorption of Zn 
in hypothyroidism patients. Additionally,  alteration in Zn distribution was apparent, for instance,  
increased absorption by other tissues including the liver, which reflects low levels of Zn in these 
patients [46]. In addition, Zn is necessary for production and activity of thyrotropin releasing 
hormone (TRH), thus increased TRH concentration in patients with hypothyroidism could be 
another explanation [7]. Moreover, Zn facilitates T3 binding to the nuclear receptor, indeed, it 
functions as a coordinating cation for DNA binding proteins [7, 47]. However, the sensitivity 
analysis found that after exclusion of Shah study [27] and Rasic-Milutinovic study [4] results 
changed; therefore, the obtained results should be interpreted cautiously. 
We found decreased Fe concentration in subgroup of subclinical hypothyroidism compared to 
healthy human adults. One possible explanation for these findings could be due to reduced 
metabolism of Fe in people with hypothyroidism, disturbed gastrointestinal absorption of Fe and 
subsequently low levels of Fe in hypothyroid patients [48]. On the other hand, thyroid hormones 
increase production of erythropoietin through direct effect on hematopoiesis [49]. Banday et al. 
[50] determined that 20-60% of people with hypothyroidism have anemia; as a result, Fe 
deficiency and reduced thyroid hormones both affect each other’s [50]. Sensitivity analysis 
revealed that results after exclusion of Hanif et al. study [11], changed to a significantly lower 
value in hypothyroidism patients compared with healthy subjects. Thus interpretation of these 
results should be drawn with caution. 
The present study found no significant difference in serum levels of Mn, Pb, Cu and Mg between 
two groups; which could be due to high heterogeneity of studies, small sample size of included 
studies, and differences in populations regarding disease activity. However, it must be noted that 
exclusion of Faisal Rashid (2010) [13] and Joao a (2007) study [29] changed results to a 
significantly higher concentration of Mn and Pb in hypothyroid patients compared with controls, 
respectively. Mn modulates thyroid secreting hormone (TSH) secretion indirectly by 
dopaminergic pathway [51]. Based on reported evidence the accumulation of Mn in the pituitary 
gland causes reduced thyroid hormones and elevated TSH concentration [52]. Pb accumulation 
in the thyroid gland leads to thyroid dysfunction [53], and might act through impairment of the 
pituitary–thyroid axis and oxido-reductive processes [53]. However more specific studies are 
needed to explain the exact correlation between these elements and hypothyroidism.  
Limitations 
The present systematic review and meta-analysis has some limitations that must be 
acknowledged. Limitations include, the high heterogeneity of included studies regarding study 
populations and disease severity, the small number of included studies, the small sample size, 
and other lifestyle and genetic background of participants which could affect final results. We 
were unable to explore priority or posteriority communication between trace elements and 
hypothyroidism due to lack of longitudinal studies. 
Conclusion 
The present meta-analysis found lower Se concentration in patients with hypothyroidism, 
whereas no significant differences in Cu, Mg, Mn, and Pb were detected between the two groups. 
In addition, we found decreased concentrations of Zn in overt hypothyroid patients and 
decreased Fe and Se level in subclinical hypothyroidism. Further studies with higher quality and 
large sample sizes are required to explicate the link between trace element and hypothyroidism. 
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